Heaton J P W, Dean J, Sleep D J
Queens University, Kingston, Ontario, Canada.
Int J Impot Res. 2002 Feb;14(1):61-4. doi: 10.1038/sj.ijir.3900831.
The response to Uprima (apomorphine sublingual, (apo SL)) has been well documented in conventional clinical trials. Apo SL produces a predictable, consistent and durable response across a wide variety of patients. The positive reinforcement of a successful outcome should further support clinical benefit. Apo SL with its rapid onset affords a greater opportunity for spontaneity, which can be an important factor in influencing patient choice. It is recognised that patient counselling and the setting of realistic expectations are vital to a successful outcome. The impact of persisting with sequential treatment on outcome has been calculated from the clinical data. While apo SL is effective de novo in 50% of single doses, additional benefit is observed with repeat dosing. Full benefit may not be achieved until four or more treatments have been taken in an optimal setting. The data also confirm that 3 mg has superior activity. Patients should therefore be encouraged to try a minimum of 4 doses at 3 mg.
在传统临床试验中，对优必上（阿扑吗啡舌下片，apo SL）的反应已有充分记录。阿扑吗啡舌下片在各类患者中都能产生可预测、一致且持久的反应。成功治疗结果带来的正强化作用应能进一步证明其临床益处。阿扑吗啡舌下片起效迅速，为自然性行为提供了更多机会，这可能是影响患者选择的一个重要因素。人们认识到，患者咨询和设定现实的期望对取得成功的治疗结果至关重要。已根据临床数据计算了持续序贯治疗对治疗结果的影响。虽然阿扑吗啡舌下片单剂量使用时50%的患者首次用药有效，但重复给药可观察到额外益处。在最佳治疗环境下，直至接受四次或更多次治疗才能达到完全疗效。数据还证实3毫克剂量具有更优活性。因此，应鼓励患者尝试至少4次3毫克剂量的治疗。
